Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07775807
Active, not recruiting Not applicable

Closed-loop TBS Targeting rPO for the Core Clinical Features of Methamphetamine Use Disorder

NCT07775807 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Mental Health Center
Phase
Not applicable
Started
2026-08-05
Last updated
2026-11-02

Condition(s) studied

Methamphetamine Use DisorderSubstance Use DisorderCue-reactivityCraving

Investigational drug(s) / intervention(s)

Closed-loop Theta-Burst Stimulation (TBS) Targeting rPO

Closed-loop Theta-Burst Stimulation (TBS) Targeting rPO: Participants receive theta-burst stimulation (TBS) over the right parietal-occipital cortex (rPO), triggered by real time by EEG signals recorded during a cue-reactivity task. This closed-loop protocol aims to deliver stimulation precisely during neural states associated with cue-induced reactivity.

Study summary

The goal of this clinical trial is to evaluate whether closed-loop theta-burst stimulation (TBS) targeting the right parietal-occipital cortex (rPO) can improve core clinical symptoms in individuals with methamphetamine use disorder (MUD), such as cue-reactivity and impaired inhibitory control.

The main questions it aims to answer are:

Can closed-loop rPO-TBS significantly reduce cue-reactivity, as measured by a Visual Analog Scale (VAS) and a cue-reactivity task? Does closed-loop stimulation enhance cognitive control, assessed by performance on the Stop Signal Task (SST)?

Researchers will administer closed loop TBS to determine whether it can improve the core symptoms of MUD.

Participants will:

Complete a single closed-loop session. Receive theta-burst stimulation targeting the right parietal-occipital cortex while completing the cue-reactivity task.

Undergo cue-reactivity assessment using a Visual Analog Scale (VAS) and complete the Stop Signal Task (SST) before and after the stimulation session.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged 18 years old or older, with at least 9 years of education (junior high school or above) or able to fully understand the task. * Meets Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) for mild/severe amphetamine-type substance use disorder. * History of amphetamine-type substance use for no less than 1 year, with use at least once per week. Exclusion Criteria: * Presence of any organic disease, or diagnosis of any other psychiatric disorder according to DSM-5 (e.g., bipolar disorder, major depression disorder). * Contraindications to TMS, as assessed by the Transcranial Magnetic Stimulation Adult Safety Screen (TASS). * Inability to complete assessments, treatment procedures, or follow-up due to cognitive or behavioral limitations.

Primary outcome measure(s)

  • Cue-Induced Neural Reactivity During Before and After Stimulation — During cue-reactivity task in training and stimulation phases of each session.
    EEG signals will be recorded while participants perform a cue-reactivity task during both the training phase (no stimulation) and the stimulation phase (with TBS). The primary outcome will be changes in cue-induced neural reactivity, defined by EEG features in response to methamphetamine-related cues.

Trial sites (1)

FacilityCityRegionStatus
Shanghai Mental Health Center, 200030 Shanghai Shanghai Municipality

More Shanghai Mental Health Center trials in China

A Study to Evaluate the Effectiveness of Group Gaming Interventions for Individuals With Problematic Gaming Behavior and Gaming Disorder. Recruiting
Home-Based Wearable rTMS Therapy for Moderate to Severe Depression Starting soon
Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder Recruiting
A Study for the Disrupted Interpersonal Interaction Among Gaming Disorder Individuals and Treatment Recruiting
Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD Recruiting

Other trials for the same condition

Cerebellum-Prefrontal Paired-Pulse Stimulation for Methamphetamine Use Disorder Recruiting
Closed-loop TMS for the Core Clinical Features of Methamphetamine Use Disorder Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07775807 on ClinicalTrials.gov ↗ ← All trials in China